The Oncosearch | Oncotarget

Combination of gemcitabine-containing magnetoliposome and oxaliplatin-containing magnetoliposome in breast cancer treatment: A possible mechanism with potential for clinical application Research Paper

Hui Ye, Jiansong Tong, Jiangyi Liu, Wenman Lin, Chengshou Zhang, Kai Chen, Jie Zhao, Wenjing Zhu

Published May 27, 2016 · Vol. 7, No. 28 · pp. 43762-43778

Bmi1 inhibition enhances the sensitivity of pancreatic cancer cells to gemcitabine Research Paper

Tao Yin, Zhengle Zhang, Bin Cao, Qingke Duan, Pengfei Shi, Hengqiang Zhao, Soriba Naby Camara, Qiang Shen, Chunyou Wang

Published May 11, 2016 · Vol. 7, No. 24 · pp. 37192-37204

Potential options for managing LOX+ ER- breast cancer patients Research Paper

Yong Han, Shenyi Lian, Xingran Cui, Kexin Meng, BalÃ¡zs GyÅ‘rffy, Tao Jin, Dongsheng Huang

Published Apr 28, 2016 · Vol. 7, No. 22 · pp. 32893-32901

The landscape of targeted therapies for cholangiocarcinoma: current status and emerging targets Review

Dawn Q. Chong, Andrew X. Zhu

Published Apr 18, 2016 · Vol. 7, No. 29 · pp. 46750-46767

Efficacy of combined gemcitabine, oxaliplatin and pegaspargase (P-gemox regimen) in patients with newly diagnosed advanced-stage or relapsed/refractory extranodal NK/T-cell lymphoma Research Paper

Jing-hua Wang, Liang Wang, Cheng-cheng Liu, Zhong-jun Xia, Hui-qiang Huang, Tong-yu Lin, Wen-qi Jiang, Yue Lu

Published Apr 8, 2016 · Vol. 7, No. 20 · pp. 29092-29101

Targeting cancer stem cells with p53 modulators Research Paper

Zhan Zhang, Ling Liu, Roberto Gomez-Casal, Xinhui Wang, Ryo Hayashi, Ettore Appella, Levy Kopelovich, Albert B. DeLeo

Published Apr 8, 2016 · Vol. 7, No. 29 · pp. 45079-45093

Analysis of the efficacy and safety of a combined gemcitabine, oxaliplatin and pegaspargase regimen for NK/T-cell lymphoma Clinical Research Papers

Jing-hua Wang, Hua Wang, Yan-jun Wang, Zhong-jun Xia, Hui-qiang Huang, Wen-qi Jiang, Yue Lu

Published Apr 7, 2016 · Vol. 7, No. 23 · pp. 35412-35422

Combined gemcitabine and S-1 chemotherapy for treating unresectable hilar cholangiocarcinoma: a randomized open-label clinical trial Research Paper

Hao Li, Zheng-Yun Zhang, Zun-Qiang Zhou, Jiao Guan, Da-Nian Tong, Guang-Wen Zhou

Published Apr 5, 2016 · Vol. 7, No. 18 · pp. 26888-26897

Lysyl oxidase family activity promotes resistance of pancreatic ductal adenocarcinoma to chemotherapy by limiting the intratumoral anticancer drug distribution Research Paper

Benjamin Le CalvÃ©, Audrey Griveau, David Vindrieux, RaphaÃ«l MarÃ©chal, Clotilde Wiel, Magali Svrcek, Johann Gout, Lamia Azzi, LÃ©a Payen, JÃ©rÃ´me Cros, Christelle de la FouchardiÃ¨re, Pierre Dubus, JÃ©rÃ´me Guitton, Laurent Bartholin, Jean-Baptiste Bachet, David Bernard

Published Apr 1, 2016 · Vol. 7, No. 22 · pp. 32100-32112

Xenopatients show the need for precision medicine approach to chemotherapy in ovarian cancer Research Paper

Jessica Erriquez, Martina Olivero, Gloria Mittica, Maria Stella Scalzo, Marco Vaira, Michele De Simone, Riccardo Ponzone, Dionyssios Katsaros, Massimo Aglietta, Raffaele Calogero, Maria Flavia Di Renzo, Giorgio Valabrega

Published Mar 24, 2016 · Vol. 7, No. 18 · pp. 26181-26191

Therapy of pancreatic cancer via an EphA2 receptor-targeted delivery of gemcitabine Research Paper

Bridget A. Quinn, Si Wang, Elisa Barile, Swadesh K. Das, Luni Emdad, Devanand Sarkar, Surya K. De, Susan Kharagh Morvaridi, John L. Stebbins, Stephen J. Pandol, Paul B. Fisher, Maurizio Pellecchia

Published Mar 5, 2016 · Vol. 7, No. 13 · pp. 17103-17110

Insights from HuR biology point to potential improvement for second-line ovarian cancer therapy Research Paper

Yu-Hung Huang, Weidan Peng, Narumi Furuuchi, James B. DuHadaway, Masaya Jimbo, Andrea Pirritano, Charles J. Dunton, Gary S. Daum, Benjamin E. Leiby, Jonathan R. Brody, Janet A. Sawicki

Published Mar 2, 2016 · Vol. 7, No. 16 · pp. 21812-21824

Ursolic acid inhibits the growth of human pancreatic cancer and enhances the antitumor potential of gemcitabine in an orthotopic mouse model through suppression of the inflammatory microenvironment Research Paper

Sahdeo Prasad, Vivek R. Yadav, Bokyung Sung, Subash C. Gupta, Amit K. Tyagi, Bharat B. Aggarwal

Published Feb 20, 2016 · Vol. 7, No. 11 · pp. 13182-13196

Integrated experimental and simulation study of the response to sequential treatment with erlotinib and gemcitabine in pancreatic cancer Research Paper

Paolo Ubezio, Francesca Falcetta, Laura Carrassa, Monica Lupi

Published Feb 19, 2016 · Vol. 7, No. 13 · pp. 15492-15506

CIP2A down regulation enhances the sensitivity of pancreatic cancer cells to gemcitabine Research Paper

Peng Xu, Jie Yao, Jin He, Long Zhao, Xiaodong Wang, Zhennan Li, Jianjun Qian

Published Feb 17, 2016 · Vol. 7, No. 12 · pp. 14831-14840

The significance of phosphorylated heat shock protein 27 on the prognosis of pancreatic cancer Research Paper

Mitsuru Okuno, Ichiro Yasuda, Seiji Adachi, Masanori Nakashima, Junji Kawaguchi, Shinpei Doi, Takuji Iwashita, Yoshinobu Hirose, Osamu Kozawa, Naoki Yoshimi, Masahito Shimizu, Hisataka Moriwaki

Published Feb 16, 2016 · Vol. 7, No. 12 · pp. 14291-14299

14-3-3Ïƒ regulation of and interaction with YAP1 in acquired gemcitabine resistance via promoting ribonucleotide reductase expression Research Paper

Li Qin, Zizheng Dong, Jian-Ting Zhang

Published Feb 15, 2016 · Vol. 7, No. 14 · pp. 17726-17736

Overcoming chemo/radio-resistance of pancreatic cancer by inhibiting STAT3 signaling Research Paper

Xiaoqing Wu, Wenhua Tang, Rebecca T. Marquez, Ke Li, Chad A. Highfill, Fengtian He, Jiqin Lian, Jiayuh Lin, James R. Fuchs, Min Ji, Ling Li, Liang Xu

Published Feb 12, 2016 · Vol. 7, No. 10 · pp. 11708-11723

The E1B19K-deleted oncolytic adenovirus mutant AdÎ”19K sensitizes pancreatic cancer cells to drug-induced DNA-damage by down-regulating Claspin and Mre11 Research Paper

Published Feb 10, 2016 · Vol. 7, No. 13 · pp. 15703-15724

miR-21 expression and clinical outcome in locally advanced pancreatic cancer: exploratory analysis of the pancreatic cancer Erbitux, radiotherapy and UFT (PERU) trial Research Paper

Khurum Khan, David Cunningham, Clare Peckitt, Sarah Barton, Diana Tait, Maria Hawkins, David Watkins, Naureen Starling, Sheela Rao, Ruwaida Begum, Janet Thomas, Jacqui Oates, Vincenza Guzzardo, Matteo Fassan, Chiara Braconi, Ian Chau

Published Feb 5, 2016 · Vol. 7, No. 11 · pp. 12672-12681

Publication Alerts

European Cancer and Oncology Congress

Post-Publication Promotion

Search Oncotarget

Combination of gemcitabine-containing magnetoliposome and oxaliplatin-containing magnetoliposome in breast cancer treatment: A possible mechanism with potential for clinical application Research Paper

Bmi1 inhibition enhances the sensitivity of pancreatic cancer cells to gemcitabine Research Paper

Potential options for managing LOX+ ER- breast cancer patients Research Paper

The landscape of targeted therapies for cholangiocarcinoma: current status and emerging targets Review

Efficacy of combined gemcitabine, oxaliplatin and pegaspargase (P-gemox regimen) in patients with newly diagnosed advanced-stage or relapsed/refractory extranodal NK/T-cell lymphoma Research Paper

Targeting cancer stem cells with p53 modulators Research Paper

Analysis of the efficacy and safety of a combined gemcitabine, oxaliplatin and pegaspargase regimen for NK/T-cell lymphoma Clinical Research Papers

Combined gemcitabine and S-1 chemotherapy for treating unresectable hilar cholangiocarcinoma: a randomized open-label clinical trial Research Paper

Lysyl oxidase family activity promotes resistance of pancreatic ductal adenocarcinoma to chemotherapy by limiting the intratumoral anticancer drug distribution Research Paper

Xenopatients show the need for precision medicine approach to chemotherapy in ovarian cancer Research Paper

Therapy of pancreatic cancer via an EphA2 receptor-targeted delivery of gemcitabine Research Paper

Insights from HuR biology point to potential improvement for second-line ovarian cancer therapy Research Paper

Ursolic acid inhibits the growth of human pancreatic cancer and enhances the antitumor potential of gemcitabine in an orthotopic mouse model through suppression of the inflammatory microenvironment Research Paper

Integrated experimental and simulation study of the response to sequential treatment with erlotinib and gemcitabine in pancreatic cancer Research Paper

CIP2A down regulation enhances the sensitivity of pancreatic cancer cells to gemcitabine Research Paper

The significance of phosphorylated heat shock protein 27 on the prognosis of pancreatic cancer Research Paper

14-3-3Ïƒ regulation of and interaction with YAP1 in acquired gemcitabine resistance via promoting ribonucleotide reductase expression Research Paper

Overcoming chemo/radio-resistance of pancreatic cancer by inhibiting STAT3 signaling Research Paper

The E1B19K-deleted oncolytic adenovirus mutant AdÎ”19K sensitizes pancreatic cancer cells to drug-induced DNA-damage by down-regulating Claspin and Mre11 Research Paper

miR-21 expression and clinical outcome in locally advanced pancreatic cancer: exploratory analysis of the pancreatic cancer Erbitux, radiotherapy and UFT (PERU) trial Research Paper

Publication Alerts

European Cancer and Oncology Congress

Oncoscience

Post-Publication Promotion

Search Oncotarget

Combination of gemcitabine-containing magnetoliposome and oxaliplatin-containing magnetoliposome in breast cancer treatment: A possible mechanism with potential for clinical application Research Paper

Bmi1 inhibition enhances the sensitivity of pancreatic cancer cells to gemcitabine Research Paper

Potential options for managing LOX+ ER- breast cancer patients Research Paper

The landscape of targeted therapies for cholangiocarcinoma: current status and emerging targets Review

Efficacy of combined gemcitabine, oxaliplatin and pegaspargase (P-gemox regimen) in patients with newly diagnosed advanced-stage or relapsed/refractory extranodal NK/T-cell lymphoma Research Paper

Targeting cancer stem cells with p53 modulators Research Paper

Analysis of the efficacy and safety of a combined gemcitabine, oxaliplatin and pegaspargase regimen for NK/T-cell lymphoma Clinical Research Papers

Combined gemcitabine and S-1 chemotherapy for treating unresectable hilar cholangiocarcinoma: a randomized open-label clinical trial Research Paper

Lysyl oxidase family activity promotes resistance of pancreatic ductal adenocarcinoma to chemotherapy by limiting the intratumoral anticancer drug distribution Research Paper

Xenopatients show the need for precision medicine approach to chemotherapy in ovarian cancer Research Paper

Therapy of pancreatic cancer via an EphA2 receptor-targeted delivery of gemcitabine Research Paper

Insights from HuR biology point to potential improvement for second-line ovarian cancer therapy Research Paper

Ursolic acid inhibits the growth of human pancreatic cancer and enhances the antitumor potential of gemcitabine in an orthotopic mouse model through suppression of the inflammatory microenvironment Research Paper

Integrated experimental and simulation study of the response to sequential treatment with erlotinib and gemcitabine in pancreatic cancer Research Paper

CIP2A down regulation enhances the sensitivity of pancreatic cancer cells to gemcitabine Research Paper

The significance of phosphorylated heat shock protein 27 on the prognosis of pancreatic cancer Research Paper

14-3-3Ïƒ regulation of and interaction with YAP1 in acquired gemcitabine resistance via promoting ribonucleotide reductase expression Research Paper

Overcoming chemo/radio-resistance of pancreatic cancer by inhibiting STAT3 signaling Research Paper

The E1B19K-deleted oncolytic adenovirus mutant AdÎ”19K sensitizes pancreatic cancer cells to drug-induced DNA-damage by down-regulating Claspin and Mre11 Research Paper

miR-21 expression and clinical outcome in locally advanced pancreatic cancer: exploratory analysis of the pancreatic cancer Erbitux, radiotherapy and UFT (PERU) trial Research Paper